Oxaliplatin in practice.

por Misset, J. L.
Publicado 1998

A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

por Zelek, L, Yovine, A, Brain, E, Turpin, F, Taamma, A, Riofrio, M, Spielmann, M, Jimeno, J, Misset, J L
Publicado 2006

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

por Bousquet, G, Alexandre, J, Le Tourneau, C, Goldwasser, F, Faivre, S, de Mont-Serrat, H, Kaiser, R, Misset, J L, Raymond, E
Publicado 2011

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Europe...

por Dieras, V., Chevallier, B., Kerbrat, P., Krakowski, I., Roche, H., Misset, J. L., Lentz, M. A., Azli, N., Murawsky, M., Riva, A., Pouillart, P., Fumoleau, P.
Publicado 1996

Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

por Brain, E., Garrino, C., Misset, J. L., Carbonero, I. G., Itzhaki, M., Cvitkovic, E., Goldschmidt, E., Burki, F., Regensberg, C., Pappo, E., Hagipantelli, R., Musset, M.
Publicado 1997

Changes in allelic imbalances in locally advanced breast cancers after chemotherapy

por Varna, M, Soliman, H, Feugeas, J-P, Turpin, E, Chapelin, D, Legrès, L, Plassa, L-F, de Roquancourt, A, Espié, M, Misset, J-L, Janin, A, de Thé, H, Bertheau, P
Publicado 2007

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study

por Roy, A, Cunningham, D, Hawkins, R, Sörbye, H, Adenis, A, Barcelo, J-R, Lopez-Vivanco, G, Adler, G, Canon, J-L, Lofts, F, Castanon, C, Fonseca, E, Rixe, O, Aparicio, J, Cassinello, J, Nicolson, M, Mousseau, M, Schalhorn, A, D'Hondt, L, Kerger, J, Hossfeld, D K, Garcia Giron, C, Rodriguez, R, Schoffski, P, Misset, J-L
Publicado 2012